BioSpace News Archive

Renovacor, Inc. (NYSE: RCOR), a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases, today reported financial results for the first quarter of 2022 and provided a corporate update.

Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), today announced that the underwriters of its previously announced initial public offering (the “IPO”) have exercised in part their over-allotment option to purchase an additional 772,091 American Depositary Shares (the “ADS”) of the Company at the IPO price of $6.00 per ADS.

Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced first quarter 2022 financial results and provided a business update.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to EDIT-301, an investigational, gene editing medicine, for the treatment of beta thalassemia.

Black Diamond Therapeutics, Inc. announced the publication of data identifying new oncogenic HER2 allosteric mutations that support the Mutation-Allostery-Pharmacology discovery engine’s capabilities and further suggest the need for novel inhibitors to treat HER2-mutant cancers.

Johnson & Johnson will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference at the Terranea Resort, Rancho Palos Verdes, CA on Thursday, June 16th.

The Medical College of Wisconsin has dedicated its Genomic Sciences and Precision Medicine Center as the Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine in honor of the couple’s $10 million gift to support new research and for MCW faculty studying the potential the human genome has to treat a wide variety of diseases.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for valbenazine as a treatment for Huntington disease (HD). The treatment of chorea associated with HD is within the scope of this Orphan Drug Designation.